Several antibody–drug conjugates (ADC) targeting Trophoblast cell surface antigen 2 (Trop-2) have been developed, demonstrating significant therapeutic efficacy in triple-negative breast cancer and non-small cell lung cancer. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.